Business Wire

Lumen Health Tech Company Reveals New Data About Metabolism Training

7.1.2021 13:32:00 EET | Business Wire | Press release

Share

Lumen, a health technology company at the forefront of metabolic health, has uncovered new data that reveals how training your metabolism is the greatest contributor to sustainable health and weight loss, not crash dieting.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210107005400/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Lumen metabolism insights (Photo: Lumen)

The data analysis is based on 1 million metabolism measurements throughout 2020, as Lumen data scientists have discovered that metabolic flexibility, or the body's ability to efficiently switch between carbs and fats as an energy source, is the key to optimal health.

By focusing on optimising their metabolism, users were able to increase metabolic flexibility by 33%. Two-thirds also reported losing weight at a rate of 2 pounds per week on a consistent basis.

On the nutrition end, users successfully completed an average of 12 hour fasts and mostly followed their personalised nutrition plan according to what their metabolism measurement prescribed. The top 2% were able to start their day in a state of burning fat for 4 consecutive days. Naturally, users also became more active and completed an average of 1000 more steps a day, and slept at least 7 hours.

That's equivalent to walking to the supermarket, doing one weekly workout at home, eating a couple carb servings per meal with room for low-carb snacks, and eating dinner by 7pm followed by a decent night of sleep.

Research (Calcada et al, Gormsen et al) finds that people with good metabolic flexibility:

  • Are in a better position to gain muscle and perform better during workouts
  • Find it easier to lose weight and maintain it; and
  • Are at lower risk of developing obesity, diabetes and metabolic disorders.

"Understanding how your body reacts to what you eat and how you exercise is crucial to training your metabolism. The base of performance, health and weight loss starts with your metabolism- and we are able to see the data of users worldwide improving their health every day just by being more aware of their body," said Barak Alon, head of data at Lumen.

In an effort to raise awareness for metabolic health and its many benefits, Lumen is launching a campaign entitled "New year, new metabolism" through a resource center with a downloadable health kit including extensive insights on nutrition and exercise to optimise metabolic health and flexibility.

About Lumen

Lumen is a device and app that measures your metabolism in a single breath through a complex algorithm and provides daily personalised nutrition based on your metabolic data. At Lumen, we believe that a healthy metabolism is the key to better health, and that everyone can attain it with a little help from Lumen.

Founded in 2014 by scientists and experienced entrepreneurs, Lumen is the biggest metabolic measurement platform in the world, with over 1,000,000 measurements per month.

Our technology provides individuals with new metrics on metabolism and a system to keep them accountable so they can achieve their health and wellness goals and prevent long-term chronic illness by improving their metabolic health.

Scientific Validation

Lumen can provide numerous insights about the metabolism of an individual, as well as valuable scientific data to increase knowledge of metabolic flexibility and nutrition. In a study conducted by San Francisco State University, Lumen has been validated to meet the gold standard for metabolic measurement.

Availability

The Lumen device is available at Lumen.me, currently priced at £299 with an MSRP of £349. The device comes equipped with a travel case, charging dock, USB-C Cable, and Premium Customer Support. Users can download the app for free on the Apple App Store and on Google Play.

Follow us on twitter.com/LumenMetabolism, facebook.com/Lumen.me/, instagram.com/lumen.me/, youtube.com/c/Lumendotme

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media contact: Kyla Blumenfeld, press@lumen.me
+972548161939

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bregal Milestone Backs Nethive With Majority Growth Investment and JoyComm Acquisition22.10.2026 11:00:00 EEST | Press release

Bregal Milestone, a leading European software growth private equity firm, today announced a majority growth investment in Nethive S.p.A. (“Nethive” or the “Company”), a leading Italian cybersecurity services and software provider. Alongside its investment in Nethive, Bregal Milestone has also backed Nethive’s acquisition of IT security specialist Joy Comm S.r.l. (“JoyComm”). Founded in 2014 by Alessandro Bellato and Diego Rocco, Nethive has become a trusted cybersecurity partner to blue-chip enterprises, SMEs, and public-sector organizations across Italy. Its platform spans managed security services, professional services and technology resale, helping organizations protect critical infrastructure and networks, strengthen cyber resilience and reduce operational complexity. Nethive combines deep technical expertise with 24/7 monitoring, threat detection and response, risk and vulnerability management, infrastructure protection and specialist consultancy. The Company serves more than 250

EOS and VOP CZ Sign Memorandum of Understanding to Explore Cooperation on Czech Programmes22.10.2026 10:00:00 EEST | Press release

EOS Defence Systems (EOS) and VOP CZ have signed a Memorandum of Understanding (MoU) at Future Forces Forum in Prague to explore cooperation on wheeled armoured vehicle programmes for the Czech Army and other future defence projects in the Czech Republic and Europe where VOP CZ is involved. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021408045/en/ EOS and VOP CZ sign a Memorandum of Understanding at Future Forces Forum in Prague. Left to right: Martin van de Voorde, Sales Director Europe, EOS; Vlastimil Navrátil, Managing Director, VOP CZ; Pavla Ungrová, Sales Director, VOP CZ; Rear Admiral Richard Caton, Australia’s Military Representative to NATO and the EU; Group Captain Michael Schleeman, Australia’s Defence Attaché; and Matej Pupák, Program Lead, VOP CZ. The agreement brings together EOS' expertise in advanced remote weapon systems (RWS) with VOP CZ's established capabilities in military vehicle integration, produ

Ferrer and Prilenia Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease22.10.2026 10:00:00 EEST | Press release

Ferreri and Prilenia Therapeutics B.V.today announced that the confirmatory Phase 3 PRECISE-HD study of investigational pridopidine in Huntington's disease (HD) has received authorization to begin in participating EU Member States (EU CT number: 2026-526093-16-00, NCT07609108). Recruitment in the EU is expected to commence this month, joining currently recruiting sites in the US and UK, with Canada to follow. Designed to evaluate the efficacy and safety of pridopidine (administered as an oral capsule twice a day), and to generate data for regulatory evaluation, the global, approximately 400-participant, randomized, double-blind, placebo-controlled PRECISE-HD study will assess the clinical effect of the investigational treatment on disease progression, functional capacity, motor function, cognition, speech and quality of life. “The initiation of PRECISE-HD in Europe marks a milestone for the Huntington’s disease research community. This confirmatory Phase 3 study has been designed to bu

IQM Quantum Computers Announces Conference Call to Report Third Quarter 2026 Financial Results on November 5, 202622.10.2026 09:00:00 EEST | Press release

As published previously, IQM Quantum Computers Plc (Nasdaq: IQMX) ("IQM" or the "Company"), a global leader in superconducting quantum computers, will report financial results for the third quarter 2026 on Thursday, November 5, 2026. CEO Dr. Jan Goetz and CFO Jan Kuerschner will host a conference call at 3:00 PM EET / 2:00 PM CET / 8:00 AM EST on the same day followed by a Q&A session with analysts. Conference Call and Webcast A live audio webcast of the conference call will be available to the public through the link below and can be accessed in the News & Events section of IQM's Investor Relations website at https://investors.iqm.tech/. A replay of the call will be available at the same location for one year following the call. Participation in the Q&A during the conference call will require registration using the link below. Date: Thursday, November 5, 2026 Time: 3:00 PM EET / 2:00 PM CET / 8:00 AM EST Webcast Link: https://edge.media-server.com/mmc/p/syqjnhp6To ask questions on the

Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance22.10.2026 08:00:00 EEST | Press release

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2026. Record net sales of 4.765 billion USD for thefirst nine months of 2026, representing 25.1% year-on-year growth at constant currency1, predominantly driven by volume and complemented by favorable mix. Broad-based double-digit growth across geographies and product categories, reflecting strong execution of Galderma’s proven integrated dermatology strategy, with stand-out performance in Therapeutic Dermatology, across both Nemluvio and the mature portfolio, as well as in Dermatological Skincare and Neuromodulators. Continued market outperformance across all three product categories, with net sales growth year-on-year at constant currency of 13.2% in Injectable Aesthetics, 16.2% in Dermatological Skincare, and 64.4% in Therapeutic Dermatology (with Nemluvio net sales of 735 million USD). Strengthening Galderma’s dermatology platform, with the pre

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye